JP2011144171A - Curative of cancer - Google Patents
Curative of cancer Download PDFInfo
- Publication number
- JP2011144171A JP2011144171A JP2010294696A JP2010294696A JP2011144171A JP 2011144171 A JP2011144171 A JP 2011144171A JP 2010294696 A JP2010294696 A JP 2010294696A JP 2010294696 A JP2010294696 A JP 2010294696A JP 2011144171 A JP2011144171 A JP 2011144171A
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- cancer
- medicine
- lignin
- disinfectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
医薬品Medicine
『カビへの招待』 中野正弘 著 研成社“Invitation to mold” by Masahiro Nakano Kenseisha
〔課題〕癌には殻があり、抗生剤が内部に浸透しないせいで光線療法や抗がん剤に頼らざるを得ず、治り難い。
〔解決法〕糖蛋白質を分解できる物質と抗生物質の混合剤は、ウイルスの尾繊維や殻、細胞の細胞壁を溶解したあと、抗生物質が細胞内での蛋白質の合成などを阻止するので癌に対する治癒力を相当レベル増強できる。キチン・セルロースは人間の構成物質ではないので溶解させても害がない。
抗生物質に混合する糖蛋白質分解物質には、発酵食品に利用されている菌による「キチン・セルロースを分解する生成物」と「キトサンジェル（注１）」を考案した。キチン・セルロースを分解する菌、および細菌は多種多様だが、モニリア−ノイロスポラ−シトフィラ（注２）を例に効果を確認することができる。
抗菌剤および抗真菌剤は作用機序の面から、〈ａ〉細胞壁合成阻害型，〈ｂ〉細菌の細胞質膜障害型，〈ｃ〉核酸合成阻害型，〈ｄ〉蛋白質合成阻害型 に分けられるが、〈ｄ〉との組合せの効果が大きく、クロラムフェニコールによる本薬剤が優れている。[Problem] Cancer has a shell, and because antibiotics do not penetrate inside, they have to rely on phototherapy and anticancer drugs and are difficult to cure.
[Solution] A mixture of a substance capable of degrading glycoproteins and antibiotics dissolves the tail fiber and shell of the virus and the cell wall of the cells, and then the antibiotics block the synthesis of proteins in the cells and prevent cancer. Healing power can be increased considerably. Chitin and cellulose are not human constituents, so there is no harm in dissolving them.
As glycoprotein degradation substances to be mixed with antibiotics, we devised “products that decompose chitin and cellulose” and “chito angel” (Note 1) by bacteria used in fermented foods. Although there are a wide variety of bacteria and bacteria that degrade chitin and cellulose, the effect can be confirmed by taking Monilia-Neurospora-Sitophila (Note 2) as an example.
Antibacterial and antifungal agents are divided into <a> cell wall synthesis inhibition type, <b> bacterial cytoplasmic membrane damage type, <c> nucleic acid synthesis inhibition type, and <d> protein synthesis inhibition type in terms of mechanism of action. However, the effect of the combination with <d> is great, and this drug by chloramphenicol is excellent.
癌が治るようになるCancer will be cured
内用薬・外用薬・注射薬Internal medicine, external medicine, injection
外用薬としては本薬剤を適用後、ポリフィルムなどで空気を１．５日位遮断することで快癒し始め、蒸気吸入では肺癌による喘息が治る。歯槽膿漏を治す。After applying this drug as a topical drug, it begins to heal by blocking air for about 1.5 days with polyfilm or the like, and asthma due to lung cancer is cured by vapor inhalation. Cure alveolar pyorrhea.
抗生物質の有為性を増強できるCan increase the potency of antibiotics
（注１）キトサンジェルについて：
キトサンジェルはキトサンを希酸で溶解したゾル物質で、カニ・エビ・魚のえら昆虫などに含まれているキチンから作られ、保湿剤として化粧品、人工皮膚の原料になっている。キトサンジェルは中和状態なので刺激性がなく、抗生物質の効力も損なわない。ここではキトサンを主成分とする保湿剤としてではなく、混入しているキトサン溶解剤と反応を促進する中和したゾル状態を必要として添加するので乾燥物でもよい。
（注２）モニリア−ノイロスポラ−シトフィラについて：
胞子はカロティンを含み、ヨーグルトや大豆によって発酵する。水溶性蛋白質、水溶性食物繊維、カルニチンを生成し、コレステロール排出作用と抗酸化作用がある。(Note 1) About Chito Angel:
Chitosan gel is a sol substance in which chitosan is dissolved in dilute acid. It is made from chitin contained in crabs, shrimps, fish gill insects, etc., and is used as a moisturizer for cosmetics and artificial skin. Since chitosan gel is in a neutral state, it is not irritating and does not impair the efficacy of antibiotics. Here, it is not a moisturizer mainly composed of chitosan, but a neutralized sol state that promotes the reaction with the mixed chitosan solubilizer is necessary and may be a dried product.
(Note 2) About Monilia-Neurospora-Sitophila:
Spores contain carotene and are fermented by yogurt or soybeans. It produces water-soluble protein, water-soluble dietary fiber, and carnitine, and has cholesterol excretion and antioxidant effects.
Claims (1)
（イ）キチン，セルロース，リグニンを分解する菌または細菌の生成物．
（ウ）抗菌剤・抗真菌剤．
（エ）殺菌剤・消毒剤．
内用薬・外用薬・注射薬全般の各医薬品の効能の一部となる、
次の組合せの混合剤
（ア）と（ウ），（イ）と（ウ），（ア）と（エ），（イ）と（エ）．(A) Chitosan gel or its dried product.
(I) Fungal or bacterial products that degrade chitin, cellulose, and lignin.
(C) Antibacterial and antifungal agents.
(D) Disinfectant / disinfectant.
It becomes part of the efficacy of each medicine for internal medicine, external medicine and injection
Mixtures of the following combinations (a) and (c), (b) and (c), (a) and (d), (b) and (d).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010294696A JP2011144171A (en) | 2010-12-05 | 2010-12-05 | Curative of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010294696A JP2011144171A (en) | 2010-12-05 | 2010-12-05 | Curative of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011144171A true JP2011144171A (en) | 2011-07-28 |
Family
ID=44459354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010294696A Pending JP2011144171A (en) | 2010-12-05 | 2010-12-05 | Curative of cancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2011144171A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9337147B2 (en) | 2000-11-20 | 2016-05-10 | Renesas Electronics Corporation | Semiconductor device and a method of manufacturing the same and designing the same |
-
2010
- 2010-12-05 JP JP2010294696A patent/JP2011144171A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9337147B2 (en) | 2000-11-20 | 2016-05-10 | Renesas Electronics Corporation | Semiconductor device and a method of manufacturing the same and designing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zagórska-Dziok et al. | Hydrogel-based active substance release systems for cosmetology and dermatology application: A review | |
| Matica et al. | Chitosan as a wound dressing starting material: Antimicrobial properties and mode of action | |
| US10143755B2 (en) | Anhydrous hydrogel composition and delivery system | |
| Burkatovskaya et al. | Use of chitosan bandage to prevent fatal infections developing from highly contaminated wounds in mice | |
| São Pedro et al. | Chitosan: an option for development of essential oil delivery systems for oral cavity care? | |
| Kumari et al. | Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products | |
| US10695301B2 (en) | Veterinary cannabinoid and menthol compositions and methods | |
| JP6239041B2 (en) | Tamarind seed polysaccharide for use in the treatment of microbial infections | |
| US9272067B2 (en) | Solid film, rapidly dissolvable in liquids | |
| EP2310052A2 (en) | Acne treatment compositions comprising nanosilver and uses | |
| Viswanathan et al. | Chlorhexidine-calcium phosphate nanoparticles—Polymer mixer based wound healing cream and their applications | |
| Rashki et al. | Delivery LL37 by chitosan nanoparticles for enhanced antibacterial and antibiofilm efficacy | |
| Dumitru et al. | Bee-derived products: chemical composition and applications in skin tissue engineering | |
| Hemmingsen et al. | The expanded role of chitosan in localized antimicrobial therapy | |
| Şenel et al. | Current status and future of delivery systems for prevention and treatment of infections in the oral cavity | |
| SE0950390L (en) | System and process for manufacturing a solution with suspended solids and uses therefor | |
| AU2011296641B2 (en) | Antifungal composition | |
| Falbo et al. | Natural compounds and biopolymers-based hydrogels join forces to promote wound healing | |
| JP2011144171A (en) | Curative of cancer | |
| Pal et al. | Chitosan: as highly potential biopolymer obtainable in several advance drug delivery systems including biomedical applications | |
| Bartley | Should chitosan and tranexamic acid be combined for improved hemostasis after sinus surgery? | |
| CN102335160B (en) | Photosensitive medicament patch and preparation method thereof | |
| CN106902133A (en) | One kind treats dermopathic medicine | |
| RU2561593C1 (en) | Combination contact-type herbal medicinal product | |
| WO2011101868A2 (en) | Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110328 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130305 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130501 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130501 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130910 |